Enasidenib in Relapsed/Refractory Mutant IDH2 AML

preview_player
Показать описание
Hetty E. Carraway, MD, discusses the supporting clinical data leading to the FDA approval of enasidenib for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Enasidenib in Relapsed/Refractory 0:04:05

Enasidenib in Relapsed/Refractory Mutant IDH2 AML

Enasidenib in mIDH 0:04:02

Enasidenib in mIDH relapsed and refractory AML

Ivosidenib or Enasidenib 0:04:42

Ivosidenib or Enasidenib in Mutant IDH1 or IDH2 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Combining Azacitadine/Enasidenib to 0:00:50

Combining Azacitadine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AML

Eytan M. Stein, 0:05:52

Eytan M. Stein, MD: Enasidenib Shows 'Encouraging' Efficacy in IDH2-Mutated AML

Phase II trial 0:02:01

Phase II trial of enasidenib in IDH2-mutant MDS

Case 3: IDH 0:05:29

Case 3: IDH Inhibitors for the Treatment of AML

Enasidenib in mutant-IDH2 0:08:26

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

Rationale for Enasidenib 0:03:05

Rationale for Enasidenib in AML

IDH1 inhibitor ivosidenib 0:01:48

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

Managing Treatment for 0:02:39

Managing Treatment for IDH2-Mutated AML

Phase I Results 0:01:24

Phase I Results for Enasidenib in AML

AML: Significance of 0:02:10

AML: Significance of the IDH2 Mutation

Dr. Al-Kali on 0:00:58

Dr. Al-Kali on FDA Approval of Enasidenib in AML

IDH inhibitors for 0:01:32

IDH inhibitors for AML and MDS

Enasidenib’s Role in 0:04:20

Enasidenib’s Role in IDH-Mutant Acute Myeloid Leukemia

IDH1/2 Inhibitors for 0:05:47

IDH1/2 Inhibitors for AML

Overall survival by 0:01:48

Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY

Treatment of Patients 0:06:15

Treatment of Patients With Chemo-Refractory AML

Acute Myeloid Leukemia: 0:52:20

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways

Targeting IDH mutations 0:02:57

Targeting IDH mutations for the treatment of AML

Advantages of Oral 0:02:11

Advantages of Oral Enasidenib in IDH2-Mutated AML

Treatment Options for 0:04:06

Treatment Options for Relapsed or Refractory AML: IDH1, IDH2, and FLT3 - Blood Cancer OncTalk

Which R/R AML 0:01:51

Which R/R AML subgroups would benefit from enasidenib treatment?

join shbcf.ru